ovaluleq.wordpress.com
Genzyme (NASDAQ: GENZ) found a virus strain and stopped production of two drugs atthe Allston, facility. The strain, Vesiviruxs 2117, apparently does not cause human infection but interrupt the growth of cell s that are used to make Aldurazyme — a treatment for MPS I, a rare and fatal disease caused by an enzyme deficiency was last filled at the Genzyme facilityy in September 2008, accordingv to BioMarin (NASDAQ: BMRN). The company has about 10 months of vialed inventorgon hand, it said, and uses a second fill finisn supplier. A third supplier is expected to be qualified laterethis year, BioMarin said. BioMarin makes the bulk material used in Aldurazyme at its Novato facility.
The Food and Drug Administratioh hadinspected Genzyme’s plant in September and October and reportedlyg was concerned about controlz to protect against contamination.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment